Pasithea Therapeutics posts investor presentation on PAS-004 MEK inhibitor program in NF1 and solid tumors

Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp.

KTTA

0.00
  • Pasithea highlighted PAS-004, a next-generation macrocyclic MEK1/2 inhibitor, as its lead program for NF1 and MAPK-driven solid tumors.
  • Interim Phase 1 readout in advanced cancers: no dose-limiting toxicities; no ocular retinal abnormalities or cardiotoxicities; treatment-related AEs were Grade 1-2.
  • Pharmacokinetics showed an estimated ~60-hour half-life in humans; cohort 7 Cmax and Cmin exceeded the cellular IC50, supporting once-daily dosing.
  • Early efficacy signal: partial response in a MEK-rechallenged patient with a BRAF V600E-mutated tumor; patient remained on study at 11 months.
  • Development plan centers on adult NF1 plexiform neurofibromas with interim results targeted for 2H 2026; management sized NF1-PN at $2+ billion TAM.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.